Osimertinib for use in the treatment of non-small cell lung cancer
AssigneeAstraZeneca AB
InventorAnthony Francis Patrick NASH
Life of this patent
Estimating the term…
Abstract
The specification relates to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for use in the treatment of EGFR TKI-naïve patients with locally-advanced or metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC), wherein the EGFR TKI is administered in combination with pemetrexed and platinum chemotherapy.
Claims16
An EGFR TKI for use in the treatment of an EGFR TKI-naïve patient with locally-advanced or metastatic EGFR mutation-positive NSCLC, wherein the EGFR TKI is administered in combination with pemetrexed and platinum chemotherapy, and wherein the EGFR TKI is either a second-generation or third-generation EGFR TKI.
An EGFR TKI for use according to any one of the proceeding claims, wherein the EGFR mutation-positive NSCLC comprises activating mutations in EGFR selected from exon 19 deletions or L858R substitution mutations.
An EGFR TKI for use according to any one of the proceeding claims, wherein the locally-advanced or metastatic EGFR mutation-positive NSCLC is a metastatic EGFR mutation-positive NSCLC.
An EGFR TKI for use according to any one of the proceeding claims, wherein the EGFR TKI is a second-generation EGFR TKI.
A method of treating locally-advanced or metastatic EGFR mutation-positive NSCLC in an EGFR TKI-naïve human patient comprising administering to the patient an EGFR TKI, wherein the EGFR TKI is administered in combination with pemetrexed and platinum chemotherapy, and wherein the EGFR TKI is either a second-generation or third-generation EGFR TKI.
The use of an EGFR TKI in the manufacture of a medicament for the treatment of an EGFR TKI-naïve patient with locally-advanced or metastatic EGFR mutation-positive NSCLC, wherein the EGFR TKI is administered in combination with pemetrexed and platinum chemotherapy, and wherein the EGFR TKI is either a second-generation or third-generation EGFR TKI.
Dependencies are inferred from the claim text.